EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

New genetic drivers in hemorrhagic hereditary telangiectasia

Pau Cerdà, Sandra D Castillo, Cinthia Aguilera, Adriana Iriarte, José Luis Rocamora, Ane M Larrinaga, Francesc Viñals, Mariona Graupera, Antoni Riera-Mestre

European Journal of Internal Medicine · 2024-01 · 119 · 99-108

DOI: 10.1016/j.ejim.2023.08.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Internal Medicine, 2024-01. Verfasst von Pau Cerdà und 8 weiteren Autor:innen. Beteiligte Einrichtung: HHT Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Internal Medicine Department, Hospital Universitari de Bellvitge, L'H…. Hauptthemen laut MEDLINE: Endothelial Cells, Telangiectasia, Hereditary Hemorrhagic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: España Ministerio de Ciencia e Innovación, Fundación La Caixa, PTEN Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsTelangiectasia, Hereditary HemorrhagicHumansMutationGenetic TestingEndoglinActivin Receptors, Type II

Stichwörter der Autor:innen

GeneticsHereditary hemorrhagic telangiectasiaHypoxiaRare diseasesSMAD6

Substanzen

EndoglinACVRL1 protein, humanActivin Receptors, Type II

Autor:innen und Institutionen

  • HHT Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Internal Medicine Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Institut d'Investigació Biomèdica de Be…
  • Endothelial Pathobiology and Microenvironment Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
  • HHT Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Genetics Laboratory, Laboratori Clín…
  • HHT Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Molecular Signaling Group, Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Institut d'Investigacio Biomedica…
  • Molecular Signaling Group, Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department…
  • Endothelial Pathobiology and Microenvironment Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; ICREA, Institució Catalana de Recerca i Estudis…

Förderung

  • España Ministerio de Ciencia e Innovación
  • Fundación La Caixa
  • PTEN Research
  • Instituto de Salud Carlos III
  • 'la Caixa' Foundation
  • Ministerio de Ciencia e Innovación
  • European Regional Development Fund

Zitieren

APA

Cerdà, P., Castillo, S. D., Aguilera, C., Iriarte, A., Rocamora, J. L., Larrinaga, A. M., Viñals, F., Graupera, M., & Riera-Mestre, A. (2024). New genetic drivers in hemorrhagic hereditary telangiectasia. European Journal of Internal Medicine, 119, 99-108. https://doi.org/10.1016/j.ejim.2023.08.024

Vancouver

Cerdà P, Castillo SD, Aguilera C, Iriarte A, Rocamora JL, Larrinaga AM, et al. New genetic drivers in hemorrhagic hereditary telangiectasia. European Journal of Internal Medicine. 2024;119:99-108. doi:10.1016/j.ejim.2023.08.024

BibTeX
@article{Cerd2024,
  author = {Cerdà, Pau and Castillo, Sandra D and Aguilera, Cinthia and Iriarte, Adriana and Rocamora, José Luis and Larrinaga, Ane M and Viñals, Francesc and Graupera, Mariona and Riera-Mestre, Antoni},
  title = {New genetic drivers in hemorrhagic hereditary telangiectasia},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {119},
  pages = {99--108},
  doi = {10.1016/j.ejim.2023.08.024}
}
Kostenlos starten →